Targeting Immunomodulation with mRNA- Based Therapeutics

Time: 11:45 am
day: Day One


  • How Ethris is employing its modified mRNA, formulation and inhaled delivery technology platforms towards development of mRNA therapeutics for treatment of lung diseases
  • Utilizing inhaled mRNA therapeutics to modulate immune responses in the lung provides novel opportunities to treat autoimmune diseases and respiratory viral infections beyond vaccines